vTv Therapeutics, Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of orally administered small-molecule drug candidates. The company's primary purpose revolves around addressing unmet medical needs by targeting chronic and debilitating diseases. vTv Therapeutics emphasizes the discovery of treatments for metabolic disorders, namely diabetes and related complications, and neurodegenerative diseases such as Alzheimer's. One of its noteworthy development candidates includes TTP399, aimed at treating Type 1 diabetes by enhancing glycemic control while reducing the risk of hypoglycemia. The company's pioneering approach lies in its proprietary technology platforms, which allow for novel oral drug candidate discoveries. Headquartered in High Point, North Carolina, vTv Therapeutics forms collaborative partnerships for the advancement of its pipeline products, influencing sectors such as healthcare and biotechnology. By prioritizing innovative oral treatments, vTv Therapeutics Inc. plays a significant role in the biopharmaceutical industry's efforts to improve patient lifestyles through novel therapeutic solutions.